Eczema Treatment non Steroidal CreamEkzembehandlung non steroidal cream
Introduction of the non-steroidal eczema ointment in the USA
New non-steroidal cream for the treatment of minor to moderately severe eczema in adult and pediatric patients 2 years and older is now available on US medical recommendation. In December, the pharmaceuticals group Pfizer obtained FDA clearance to commercialize Eucrisa (crisaborole). "Eucrisa registration is good news not only for pediatric and adult patients who suffer from minor to moderately severe eczema, a population that has had no new prescriptive treatment for more than 10 years," said Albert Bourla, group leader of Pfizer Innovative Health.
Using two placebo-controlled studies with a population of 1,522, the scientists investigated both the efficacy and efficacy of the cream and applied the anti-inflammatory cream twice daily. Eucrisa was an efficient treatment for most people, according to the research team. Approximately 50 percent of the study subjects who used the cream said that their eczema had dissolved in less than a whole month. However, the number of people who did not use the cream was still high.
Whilst side reactions were rare in the trials, investigators say that a serious side effect of Eucrisa was the "hypersensitivity reaction". It is recommended that those who react to CRISABAROLE should not use it.
Non-steroidal treatment of eczema: Results of a monitored and Randomized Trial. - pubMed
Objective: This trial evaluated the effectiveness of a new non-steroidal anti-inflammatory drug compared to hydrocortisone butyrate 0.1% cream in curing eccematous dermatitis. 3. METHODS: Bi-lateral randomised control randomised trial was performed in adult volunteers with eczema in Italy with at least two symmetrical early trial lesion sites associated with non-steroidal cream or hydrocortisone.
Gravity of lesion was assessed using the Global Clinical Score (GCS) and recuperation was set to 0 GSC: 1 ) the difference in GCS between four points in treatment (baseline, four, eight, twelve weeks) depending on the drug administered; 2) treatment outcomes.
RESULTS: The trial showed that GCS was associated with timing, treatment, and interactions between treatment and timing; in addition, the hydrocortisone lesion treatment was better overall, but post-hoc analyses showed significant improvement in clinic at all times only for the non-steroid cream. By the end of the trial, with the intent of treating the analyses, the lesion recovers in 76.1% and 40.3% of the cases with hydrocortisone and non-steroid cream, respectively; in the protocollar populations, the recuperation was reached in 91.7% and 58.3% of the cases, respectively.
RESULTS: The results show that the non-steroid cream has been shown to be efficacious in the reduction of the seriousness of eczema and can be used with continued efficacy in the long-term treatment of the ailment.